


# Monograph



## Quercetin

### Description

Quercetin is widely distributed in the plant kingdom and is the most abundant of the flavonoid molecules. It is found in many often-consumed foods, including apple, onion, tea, berries, and brassica vegetables, as well as many seeds, nuts, flowers, barks, and leaves. It is also found in medicinal botanicals, including *Ginkgo biloba*, *Hypericum perforatum* (St. John's Wort), *Sambucus canadensis* (Elder), and many others. It is often a major component of the medicinal activity of the plant, and has been shown in experimental studies to have numerous effects on the body.

All flavonoids have the same basic chemical structure, a three-ringed molecule with hydroxyl (OH) groups attached (see Figure). A multitude of other substitutions can occur, giving rise to the many types of flavonoids. Flavonoids often occur in foods as a glycoside, meaning they have a sugar molecule (rhamnose, glucose, galactose, etc.) attached to the center (C) ring. Quercetin is the aglycone (meaning minus the sugar molecule) of a number of other flavonoids, including rutin, quercetrin, isoquercetin, and hyperoside. These molecules have the same structure as quercetin except they have a specific sugar molecule in place of one of quercetin's hydroxyl groups on the C ring, which dramatically changes the activity of the molecule. Activity comparison studies have identified other flavonoids as often having similar effects as quercetin; but quercetin usually has the greatest activity.

Quercetin appears to have many beneficial effects on human health, including cardiovascular protection, anti-cancer activity, anti-ulcer effects, anti-allergy activity, cataract prevention, antiviral activity, and anti-inflammatory effects.

### Mechanisms of Action

Flavonoids, as a rule, are antioxidants, and a number of quercetin's effects appear to be due to its antioxidant activity. Quercetin scavenges oxygen radicals,<sup>1,2</sup> inhibits xanthine oxidase,<sup>3</sup> and inhibits lipid peroxidation *in vitro*.<sup>4</sup> As another indicator of its antioxidant effects, quercetin inhibits oxidation of LDL cholesterol *in vitro*, probably by inhibiting LDL oxidation itself, by protecting vitamin E in LDL from being oxidized or by regenerating oxidized vitamin E.<sup>5</sup> By itself, and paired with ascorbic acid, quercetin reduced the incidence of oxidative damage to neurovasculature structures in skin, and inhibited damage to neurons caused by experimental glutathione depletion.<sup>6</sup>

Quercetin's anti-inflammatory activity appears to be due to its antioxidant and inhibitory effects on inflammation-producing enzymes (cyclooxygenase, lipoxygenase) and the subsequent inhibition of inflammatory mediators, including leukotrienes and prostaglandins.<sup>7,8</sup> Inhibition of histamine release by mast cells and basophils<sup>9,10</sup> also contributes to quercetin's anti-inflammatory activity.

Aldose reductase, the enzyme which catalyzes the conversion of glucose to sorbitol, is especially important in the eye, and plays a part in the formation of diabetic cataracts. Quercetin is a strong inhibitor of human lens aldose reductase.<sup>11</sup>

Quercetin exerts antiviral activity against reverse transcriptase of HIV and other retroviruses, and was shown to reduce the infectivity and cellular replication of Herpes simplex virus type 1, polio-virus type 1, parainfluenza virus type 3, and respiratory syncytial virus (RSV).<sup>12</sup>

Early studies on quercetin reported that administration to rats caused an increased incidence of urinary bladder tumors. Subsequent studies on rats, mice, and hamsters were unable to confirm the potential carcinogenicity of this molecule.<sup>13,14</sup> In fact, much of the recent research on quercetin has shown it to be an anticarcinogen to numerous cancer cell types, including breast,<sup>15-17</sup> leukemia,<sup>18,19</sup> colon,<sup>20</sup> ovary,<sup>21,22</sup> squamous cell,<sup>23</sup> endometrial,<sup>21</sup> gastric,<sup>24</sup> and non-small-cell lung.<sup>25</sup>

## Clinical Indications

**Allergies:** Quercetin's mast-cell-stabilizing effects make it an obvious choice for use in preventing histamine release in allergy cases, similar to the synthetic flavonoid analogue cromolyn sodium. Absorption of the pure aglycone quercetin is poor (see below); however, much of quercetin's anti-allergy effects may be due to anti-inflammatory and anti-histaminic effects in the gut.

**Cardiovascular Disease Prevention:** Quercetin's cardiovascular effects center on its antioxidant and anti-inflammatory activity, and its ability to inhibit platelet aggregation *ex vivo*.<sup>26</sup> The Zutphen Elderly Study investigated dietary flavonoid intake and risk of coronary heart disease. The risk of heart disease mortality decreased significantly as flavonoid intake increased. Individuals in the upper 25 percent of flavonoid intake had a relative risk of 0.42 compared to the lowest 25 percent in this 5-year follow-up study of men ages 65-84. Interestingly, the flavonoid-containing foods most commonly eaten in this study contain a high amount of quercetin (tea, onions, apples).<sup>27</sup> In a cohort of the same study, dietary flavonoids (mainly quercetin) were inversely associated with stroke incidence.<sup>28</sup>

**Inflammation:** Quercetin is indicated in any inflammatory condition, as it inhibits the formation of the inflammatory mediators prostaglandins and leukotrienes, as well as histamine release. This may be especially helpful in asthma, as leukotriene B4 is a potent bronchial constrictor. Quercetin's inhibition of xanthine oxidase decreases the formation of uric acid, and thus it may be of value in the treatment of gout.

**Anti-ulcer/Gastroprotective effects:** Animal studies have shown quercetin to be protective of gastric ulceration caused by ethanol, probably by inhibiting lipid peroxidation of gastric cells<sup>29,30</sup> and/or by inhibition of gastric acid secretion.<sup>31</sup> An interesting aspect of quercetin's anti-ulcer effect is that it has been shown to inhibit growth of *Helicobacter pylori* in a dose-dependent manner *in vitro*.<sup>31</sup>

**Cancer:** As mentioned above, quercetin has been investigated in a number of animal models and human cancer cell lines, and has been found to have antiproliferative effects. It may also increase the effectiveness of chemotherapeutic agents.<sup>21,22</sup> More clinically-oriented research needs to be done in this area to discover effective dosage ranges and protocols.

**Diabetic Complications:** Quercetin's aldose reductase-inhibiting properties make it a useful addition to diabetic nutritional supplementation, to prevent cataract and neurovascular complications.

**Viral Infections:** Quercetin may be useful in viral infections; however, none of the research so far is clinically-based. Even so, concentration on ingesting quercetin-rich foods or supplementation with the pure substance may be helpful during viral illnesses.

## Pharmacokinetics

Few human quercetin absorption studies exist. It appears that only a small percentage of quercetin is absorbed after an oral dose, possibly only two percent, according to one study.<sup>32</sup> A recent study of absorption in “healthy” ileostomy patients revealed an absorption of 24 percent of the pure aglycone and 52 percent of quercetin glycosides from onions.<sup>33</sup> However, no intestinal permeability values were obtained in this group, and thus the results might not be reliable. Quercetin undergoes bacterial metabolism in the intestinal tract, and is converted into phenolic acids. Absorbed quercetin is transported to the liver bound to albumin, where some may be converted via methylation, hydroxylation, or conjugation.<sup>34</sup>

## Dosage

An oral dose of 400-500 mg three times per day is typically used in clinical practice. Since solubility is an issue in quercetin absorption,<sup>34</sup> a new, water-soluble quercetin molecule, quercetin chalcone, might be used in smaller doses, typically 250 mg three times per day.

## References

1. Saija A, Scalese M, Lanza M, et al. Flavonoids as antioxidant agents: importance of their interaction with biomembranes. *Free Radic Biol Med* 1995;19:481-486.
2. Miller AL. Antioxidant flavonoids: structure, function and clinical usage. *Alt Med Rev* 1996;1:103-111.
3. Chang WS, Lee YJ, Lu FJ, Chiang HC. Inhibitory effects of flavonoids on xanthine oxidase. *Anticancer Res* 1993;13:2165-2170.
4. Chen YT, Zheng RL, Jia ZJ, Ju Y. Flavonoids as superoxide scavengers and antioxidants. *Free Radic Biol Med* 1990;9:19-21.
5. DeWhalley CV, Rankin JF, Rankin SM, et al. Flavonoids inhibit the oxidative modification of low density lipoproteins. *Biochem Pharmacol* 1990;39:1743-1749.
6. Skaper SD, Fabris M, Ferrari V, et al. Quercetin protects cutaneous tissue-associated cell types including sensory neurons from oxidative stress induced by glutathione depletion: cooperative effects of ascorbic acid. *Free Radic Biol Med* 1997;22:669-678.
7. Della Loggia “, Ragazzi E, Tubaro A, et al. Anti-inflammatory activity of benzopyrones that are inhibitors of cyclo- and lipo-oxygenase. *Pharmacol Res Commun* 1988;20:S91-S94.
8. Kim HP, Mani I, Ziboh VA. Effects of naturally-occurring flavonoids and biflavonoids on epidermal cyclooxygenase from guinea pigs. *Prostaglandins Leukot Essent Fatty Acids* 1998;58:17-24.
9. Fox CC, Wolf EJ, Kagey-Sobotka A, Lichtenstein LM. Comparison of human lung and intestinal mast cells. *J Allergy Clin Immunol* 1988;81:89-94.
10. Bronner C, Landry Y. Kinetics of the inhibitory effect of flavonoids on histamine secretion from mast cells. *Agents Actions* 1985;16:147-151.
11. Chaudry PS, Cabera J, Juliani HR, Varma SD. Inhibition of human lens aldose reductase by flavonoids, sulindac, and indomethacin. *Biochem Pharmacol* 1983;32:1995-1998.
12. Kaul TN, Middleton E Jr, Ogra PL. Antiviral effect of flavonoids on human viruses. *J Med Virol* 1985;15:71-79.
13. Stavric B. Quercetin in our diet: from potent mutagen to probable anticarcinogen. *Clin Biochem* 1994;27:245-248.

14. Hertog MGL, Hollman PCH. potential health effects of the dietary flavonol quercetin. *Eur J Clin Nutr* 1996;50:63-71.
15. Scambia G, Raneletti FO, Panici PB, et al. Quercetin induces type-II estrogen-binding sites in estrogen-receptor-negative (MDA-MB231) and estrogen-receptor-positive (MCF-7) human breast-cancer cell lines. *Int J Cancer* 1993;54:462-466.
16. Scambia G, Raneletti FO, Panici PB, et al. Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites. *Cancer Chemother Pharmacol* 1991;28:255-258.
17. Singhal RL, Yeh YA, Prajda N, et al. Quercetin down-regulates signal transduction in human breast carcinoma cells. *Biochem Biophys Res Comm* 1995;208:425-431.
18. Larocca LM, Teofili L, Sica S, et al. Quercetin inhibits the growth of leukemic progenitors and induces the expression of transforming growth factor-B1 in these cells. *Blood* 1995;85:3654-3661.
19. Larocca LM, Teofili L, Leone G, et al. Antiproliferative activity of quercetin on normal bone marrow and leukaemic progenitors. *Br J Haematol* 1991;79:562-566.
20. Pereira MA, Grubbs CJ, Barnes LH, et al. Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenzy[a]anthracene-induced mammary cancer in rats. *Carcinogenesis* 1996;17:1305-1311.
21. Scambia G, Raneletti FO, Panici PB, et al. Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum(II). *Gynecol Oncology* 1992;45:13-19.
22. Scambia G, Raneletti FO, Panici PB, et al. Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth. *Anticancer Drugs* 1990;1:45-48.
23. Castillo MH, Perkins E, Campbell JH. The effects of the bioflavonoid quercetin on squamous cell carcinoma of head and neck origin. *Am J Surg* 1989;158:351-355.
24. Yoshida M, Sakai T, Hosokawa N, et al. The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. *FEBS Letters* 1990;260:10-13.
25. Caltagirone S, Raneletti FO, Rinelli A, et al. Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer. *Am J Resp Cell Mol Biol* 1997;17:51-59.
26. Pace-Asciak CR, Hahn S, Diamandis EP, et al. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. *Clin Chim Acta* 1995;235:207-219.
27. Hertog MG, Feskens EJ, Hollman PC, et al. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. *Lancet* 1993;342:1007-1011.
28. Keli SO, Hertog MG, Feskens EJ, Kromhout D. Dietary flavonoids, antioxidant vitamins, and incidence of stroke: the Zutphen study. *Arch Intern Med* 1996;156:637-642.
29. Alarcón de la Lastra C, Martín MJ, Motilva V. Antiulcer and gastroprotective effects of quercetin: a gross and histologic study. *Pharmacology* 1994;48:56-62.
30. Mizui T, Sato H, Hirose F, Doteuchi M. Effect of antiperoxidative drugs on gastric damage induced by ethanol in rats. *Life Sci* 1987;41:755-763.
31. Beil W, Birkholz C, Sewing KF. Effects of flavonoids on parietal cell acid secretion, gastric mucosal prostaglandin production and Helicobacter pylori growth. *Arzneimittelforschung* 1995;45:697-700.
32. Gugler R, Leschik M, Dengler HJ. Disposition of quercetin in man after single oral and intravenous doses. *Eur J Clin Pharmacol* 1975;9:229-234.
33. Hollman PC, de Vries JH, van Leeuwen SD, et al. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. *Am J Clin Nutr* 1995;62:1276-1282
34. Manach C, Regeat F, Texier O, et al. Bioavailability, metabolism and physiological impact of 4-oxo-flavonoids. *Nutrition Research* 1996;16:517-534.